NeoGenomics Q3FY26 Results: Revenue ~$209M, Guidance Reiterated
- NeoGenomics reported Q3 revenue of approximately $209 million
- Full-year FY2026 revenue and adjusted EBITDA guidance remain unchanged
- Company plans to raise the revenue guidance midpoint on the earnings call
*this image is generated using AI for illustrative purposes only.
NeoGenomics Inc reported third-quarter fiscal year 2026 revenue of approximately $209 million. The company reiterated its full-year FY2026 revenue and adjusted EBITDA guidance.
Management indicated that it expects to raise the midpoint of its full-year revenue guidance during the upcoming quarterly earnings call. This update suggests confidence in the current trajectory despite maintaining the broader annual outlook for now.
Financial Highlights
The key financial metrics disclosed in the preliminary announcement are summarized below:
| Metric | Value | Status |
|---|---|---|
| Q3 Revenue | ~$209 million | Reported |
| FY2026 Revenue Guidance | Unchanged | Reiterated |
| FY2026 Adjusted EBITDA Guidance | Unchanged | Reiterated |
| Revenue Guidance Midpoint | To be raised | Expected update |
What the Numbers Show
The decision to reiterate full-year guidance while simultaneously signaling an increase in the revenue guidance midpoint indicates a divergence between conservative initial targets and actual performance trends. By holding the total range steady but lifting the central expectation, NeoGenomics is acknowledging stronger-than-anticipated top-line momentum without committing to a higher upper bound until formal confirmation on the call.
What specific end-market segments or product lines are driving the stronger-than-expected top-line momentum in Q3?
How might the anticipated raise in revenue guidance midpoint impact analyst consensus estimates for FY2026?
Are there any emerging competitive pressures or regulatory changes that could constrain the upper bound of future revenue guidance?
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
